Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]), a Cambridge, MA, biotech firm working on RNAi-based therapies, said today that pharmaceutical giant Novartis had exercised an option to purchase approximately $5.4 million worth of Alnylam’s unregistered shares (i.e. restricted shares that were never offered for sale on the public market). The purchase boosts Novartis’s ownership stake in Alnylam slightly, from 13 percent to 13.4 percent.
Author: Wade Roush
Between 2007 and 2014, I was a staff editor for Xconomy in Boston and San Francisco.
Since 2008 I've been writing a weekly opinion/review column called VOX: The Voice of Xperience. (From 2008 to 2013 the column was known as World Wide Wade.)
I've been writing about science and technology professionally since 1994. Before joining Xconomy in 2007, I was a staff member at MIT’s Technology Review from 2001 to 2006, serving as senior editor, San Francisco bureau chief, and executive editor of TechnologyReview.com. Before that, I was the Boston bureau reporter for Science, managing editor of supercomputing publications at NASA Ames Research Center, and Web editor at e-book pioneer NuvoMedia.
I have a B.A. in the history of science from Harvard College and a PhD in the history and social study of science and technology from MIT. I've published articles in Science, Technology Review, IEEE Spectrum, Encyclopaedia Brittanica, Technology and Culture, Alaska Airlines Magazine, and World Business, and I've been a guest of NPR, CNN, CNBC, NECN, WGBH and the PBS NewsHour. I'm a frequent conference participant and enjoy opportunities to moderate panel discussions and on-stage chats.
My personal site: waderoush.com
My social media coordinates:
Twitter: @wroush
Facebook: facebook.com/wade.roush
LinkedIn: linkedin.com/in/waderoush
Google+ : google.com/+WadeRoush
YouTube: youtube.com/wroush1967
Flickr: flickr.com/photos/wroush/
Pinterest: pinterest.com/waderoush/
View all posts by Wade Roush